Back

Epigenetically constrained astrocyte states underlie prefrontal cortex vulnerability in Down syndrome associated Alzheimer disease

Sun, C.; Thomas, R.; Stringer, C.; Galani, K.; Ho, L.-L.; Sun, N.; Renfro, A.; Wright, S.; Firenze, R.; Tsai, L.-H.; Head, E.; Kellis, M.; Yang, J.

2026-04-21 bioinformatics
10.64898/2026.04.17.719050 bioRxiv
Show abstract

Down syndrome (DS), caused by trisomy 21, confers a near-universal risk for Alzheimers disease (AD), yet individuals exhibit marked variability in cognitive decline, suggesting the presence of cellular mechanisms that modulate vulnerability and resilience. However, these mechanisms remain poorly defined in the human brain. Here, we integrate matched single-nucleus RNA-seq and ATAC-seq profiles from the prefrontal cortex (PFC) and amygdala (AMY) of age-matched individuals with DS with and without AD (DSAD), enabling direct comparison within a shared genetic background. We identify basal astrocytes in the PFC as a selectively vulnerable cell state in DSAD, characterized by both reduced abundance and coordinated transcriptional and regulatory reprogramming. This state exhibits a shift away from homeostatic support functions, with decreased cytokine signaling and lipid-handling programs, alongside increased steroid- and nuclear receptor-associated activity. Concomitantly, chromatin accessibility profiling reveals reduced engagement of immune- and stress-responsive transcription factor programs, including AP-1, STAT, and BACH families, with linked regulatory perturbations at loci such as ABCA1, DAB2IP, and IL1RAP. Together, these findings define a previously unrecognized astrocyte state marked by epigenetic constraint and diminished responsiveness to stress and inflammatory signals, distinguishing it from classical reactive astrocyte phenotypes. Our results nominate PFC basal astrocytes as a key locus of vulnerability in DSAD and suggest that failure to mount appropriate astrocyte responses, rather than overt activation alone, may contribute to neurodegenerative progression.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Nature Communications
4913 papers in training set
Top 6%
18.2%
2
Molecular Cell
308 papers in training set
Top 0.8%
14.1%
3
Nature Metabolism
56 papers in training set
Top 0.2%
7.0%
4
Nature Genetics
240 papers in training set
Top 1%
6.7%
5
Science
429 papers in training set
Top 9%
3.5%
6
Alzheimer's & Dementia
143 papers in training set
Top 1%
3.5%
50% of probability mass above
7
Cell Reports
1338 papers in training set
Top 17%
3.2%
8
Nature Cell Biology
99 papers in training set
Top 2%
2.7%
9
Nature
575 papers in training set
Top 8%
2.5%
10
Advanced Science
249 papers in training set
Top 8%
2.5%
11
Cell Genomics
162 papers in training set
Top 2%
2.5%
12
Science Advances
1098 papers in training set
Top 11%
2.4%
13
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 28%
2.1%
14
eLife
5422 papers in training set
Top 46%
1.5%
15
Science Immunology
81 papers in training set
Top 1%
1.5%
16
Genome Medicine
154 papers in training set
Top 5%
1.5%
17
Nature Cardiovascular Research
28 papers in training set
Top 0.3%
1.5%
18
Cell
370 papers in training set
Top 13%
1.5%
19
Immunity
58 papers in training set
Top 3%
1.3%
20
Cell Systems
167 papers in training set
Top 10%
0.9%
21
Nature Chemical Biology
104 papers in training set
Top 3%
0.9%
22
Nucleic Acids Research
1128 papers in training set
Top 15%
0.9%
23
Nature Medicine
117 papers in training set
Top 4%
0.9%
24
Nature Biotechnology
147 papers in training set
Top 7%
0.9%
25
Nature Neuroscience
216 papers in training set
Top 6%
0.9%
26
Aging Cell
144 papers in training set
Top 3%
0.9%
27
JCI Insight
241 papers in training set
Top 6%
0.9%
28
Molecular Psychiatry
242 papers in training set
Top 3%
0.8%
29
Nature Aging
51 papers in training set
Top 2%
0.7%
30
Genome Biology
555 papers in training set
Top 9%
0.6%